D
isease response to medical treatment of Crohn's disease (CD) and ulcerative colitis (UC) has traditionally been assessed using the resolution of patient symptoms, as measured by clinical disease activity indices such as the Crohn's Disease Activity Index, the Harvey Bradshaw Index (HBI), and the partial Mayo score. 1, 2 However, the targeting of mucosal healing (MH), rather than symptomatic response, is associated with improved clinical outcomes for both CD and UC, reducing the risk of surgery, steroid dependence, and hospitalization, while increasing the likelihood of achieving deep, sustained remission. [3] [4] [5] [6] Assessment of MH using symptom scoring for patients with inflammatory bowel disease (IBD) are frequently discordant with actual endoscopic findings: a substantial subset of patients demonstrates active mucosal inflammation despite symptomatic remission. For example, in subgroup analysis of the Study of Biologic and Immunomodulator Naive Patients in CD randomized controlled trial, Peyrin-Biroulet et al 7 reported that only 53% of patients with clinical remission by CD Activity Index had achieved MH. Thus, endoscopic assessment remains the gold standard for evaluation of MH status; however, frequent colonoscopy is invasive, inconvenient, expensive, impractical, and associated with risk for procedural complications. 8 Fecal biomarkers for mucosal inflammation are a potential noninvasive alternative that could be used to evaluate MH. Fecal calprotectin (FCP), a cytosolic granulocyte protein associated with neutrophil migration to the intestinal tract, is sensitive for identifying mucosal inflammation, prognosticating treatment response, and predicting disease relapse. [9] [10] [11] In addition, there is growing interest in using fecal immunochemical testing (FIT) for stool hemoglobin. Commonly used for colorectal cancer screening, FIT has also been demonstrated to be sensitive for the detection of inflammatory disease manifesting as mucosal ulceration and occult blood loss. [12] [13] [14] While an elevated FIT and FCP are both sensitive for detecting mucosal inflammation, the specificity of a low FIT, and/ or FCP for MH has not been validated. If, in fact, fecal biomarkers accurately predict MH, they could be used to replace surveillance endoscopy in at least a subset of patients. Furthermore, FIT and FCP testing frequently already occurs in the context of other data gathering, including clinical and serological assessments. Even so, few studies have incorporated these fecal biomarkers into their multivariate predictive modeling.
In this study, we prospectively evaluated the specificity of FIT and FCP for predicting MH in an adult IBD patient cohort. We then used multivariate logistic regression to define a clinically relevant noninvasive prediction model for identifying MH. We hypothesized that by combining data from a fecal biomarker for mucosal ulceration and bleeding (FIT) with that from a biomarker for inflammation (FCP), more specific noninvasive prediction of MH could be achieved.
MATERIALS AND METHODS

Patient Cohort
Consecutive adult ($18 yr) ambulatory patients with IBD scheduled for outpatient colonoscopy between March 1, 2015 and June 30, 2015 and attending the tertiary care referral center at the University of Alberta IBD Clinic were prospectively invited to participate in this study. Chart reviews and patient interviews were used to identify eligible patients with CD or UC diagnoses (as established by history, endoscopy, or histology). Exclusion criteria included therapeutic dose anticoagulation, previous proctocolectomy, suspected IBD undergoing a diagnostic colonoscopy, incomplete colonoscopy (secondary to inadequate bowel preparation, procedural complications, limited proctosigmoidoscopy, or inability to intubate the terminal ileum in patients with CD), and inappropriate stool collection (collection after laxative bowel preparation regimen; inappropriately stored stool samples). The intended sample size was an 80-patient cohort.
FIT and FCP Testing
Participating patients collected stool samples within 48 hours of their scheduled colonoscopy and before starting the bowel preparation regimen. Patients were provided with stool sample collection kits for FIT and FCP; their specific instructions were to collect first morning stool samples for both tests and store the samples under refrigerated conditions after collection. Stool samples were provided to the investigators at the time of colonoscopy for processing. Proper collection and storage were confirmed at the time of colonoscopy, and patients were excluded from the study if there was any deviance from the stool sample collection protocol.
FIT was measured using the automated OC-Sensor Diana system (Somagen Diagnostics Inc., Edmonton, Canada), which quantifies fecal hemoglobin, using a polyclonal latex immunoturbidimetry assay within a calibration range of 0 to 1000 ng/mL. Stools with a hemoglobin concentration .1000 ng/mL were identified as frankly bloody and were not further diluted in our study. FCP was measured using a quantitative enzyme-linked immunosorbent assay (Bühlmann Laboratories AG, Schönenbuch, Switzerland). The assay has a range of 30 to 1800 mg/g and has been previously well validated. Stool samples with FCP levels above the upper limit were further diluted to obtain a quantitative value.
Clinical Measures of Disease Activity
Patients' blood samples were collected within 1 week of colonoscopy and assessed for complete blood count including hemoglobin, albumin, C-reactive protein (CRP), and ferritin. Patients were also clinically assessed using a comprehensive questionnaire supplemented by chart reviews for smoking status, IBD treatment history, current IBD therapy (corticosteroids, 5-aminosalicylic acid agents, immunomodulators, and biologics), hospitalization and surgical history, Clostridium difficile infection status, previous endoscopic assessment(s), and current clinical disease activity as assessed by either the HBI 1 for CD or partial Mayo score 15 for UC. Clinical remission was defined as an HBI ,5 or partial Mayo score ,2.
Endoscopic Measures of Disease Activity
Each study patient received either a 4L polyethylene glycol-based or a 2-dose sodium picosulfate-based bowel cleansing regimen before colonoscopy. Endoscopic assessment was performed by 1 of 6 gastroenterologists (R.N.F., B.P.H., L.A. D., K.I.K., K.W., and V.W.H.), all of whom have advanced training in IBD assessment. The gastroenterologists were blinded to serology and stool testing results at the time of colonoscopy.
Mucosal status in UC was assessed using the UC Endoscopic Index of Severity (UCEIS), 16 which evaluates vascular pattern, bleeding, and erosions or ulcerations in the most inflamed colonic segment. MH was defined as a UCEIS score of 3 (normal vasculature, no bleeding, and no erosions/ulcerations throughout the colon). For patients with CD, the Simple Endoscopic Score for CD (SES-CD) 17 was used to evaluate each bowel segment (rectum, sigmoid colon, transverse colon, right colon, and terminal ileum) for ulceration size, ulcerated surface, affected surface area, and presence of narrowing. A total SES-CD score of 0 for all bowel segments was defined as MH. For patients with CD with previous resection, MH was defined as a Rutgeerts score 18 of grade i0 (no lesions and normal anastomosis and neoterminal ileum for at least 10 cm).
Statistical Analysis
Baseline patient characteristics were analyzed using standard descriptive statistics. Sensitivity, specificity, and positive and negative predictive values (PPV, NPV) for FIT and FCP for MH were calculated. Receiver operator characteristic curves were constructed, and the areas under the curve (AUC) for FIT and FCP were compared using the Hanley and McNeil method 19 with a P value , 0.05 considered statistically significant. Subgroup analysis by disease (CD versus UC) was performed. Spearman's rank correlations were used to evaluate the association between FIT and FCP. Multivariate logistic regression analysis was then used to develop a model for noninvasive prediction of MH. The following variables were considered for inclusion: clinical variables (sex, smoking, and disease activity index scores), serological variables (albumin and CRP), and fecal testing (FIT and FCP). Odds ratios with 95% confidence interval were estimated for the effect of each variable on the log odds of MH. Best subset selection was then used to identify the combination of variables which provided the greatest predictive power for MH. 20 Variables in the univariate analysis associated with a P value , 0.05 for MH were included in the final model. Sensitivity, specificity, PPV, and NPV were estimated as measures of diagnostic accuracy of the full model.
Statistical analysis was performed using SPSS 24.0 (IBM Corp., Armonk, NY) and STATA 14 (StataCorp LP., College Station, TX).
ETHICAL CONSIDERATIONS
This study was approved by the Human Research Ethics Board at the University of Alberta.
RESULTS
Patient Characteristics
The patient recruitment process is outlined in Figure 1 . Eighty patients (40 UC, 40 CD) met the study inclusion criteria and underwent complete colonoscopy. Baseline disease characteristics are summarized in Table 1 . Disease extent was predominantly ileal among patients with CD (20/40, 50.0%) and pancolonic among patients with UC (24/40, 60.0%). Median disease duration for the whole cohort was 11.0 years (interquartile range [IQR]: 5.8-25.3 yr). Twenty-one patients with UC (52.5%) were clinically in remission with a partial Mayo score ,2; 31 patients with CD (77.5%) were in remission with an HBI ,5. At colonoscopy, 50 patients (26 CD, 24 UC) were shown to have MH.
FIT and FCP Results
Among all patients, median FIT was 17 ng/mL (IQR: 8-235 ng/mL) and median FCP was 322 mg/g (IQR: 202-606 mg/g). There was no difference in median FIT (15 versus 30 ng/mL, P ¼ 0.37) or FCP (330 versus 322 mg/g, P ¼ 0.61) between CD and UC. Fifty-eight patients (72.5%) had an FIT ,100 ng/mL, whereas 31 patients (38.8%) had an FCP ,250 mg/g. Eleven patients (13.8%) had FIT .1000 ng/mL; 8 of these patients had UC. There was a modestly positive correlation between FIT and FCP (Spearman rank correlation coefficient r s ¼ 0.55, P , 0.01); correlation between these 2 tests was stronger among patients with UC (r s ¼ 0.63, P , 0.001) than for those with CD (r s ¼ 0.50, P ¼ 0.001).
FIT and FCP for Identifying MH
Sensitivity, specificity, PPV, and NPV of FIT and FCP for MH are shown in Table 2 . Among all patients, an FIT cutoff of 100 ng/mL identified MH with a specificity of 0.57 (95% confi- For both FIT and FCP, sensitivity, specificity, PPV, and NPV for identifying MH were higher for patients with UC than for those with CD (Table 2) (Fig. 2B, C) . This trend is predominantly driven by the weaker performance of FIT and FCP in patients with ileal CD: in subgroup analysis of patients with CD with isolated colonic disease, performance characteristics for FIT (AUC 0.83 versus 0.88, P ¼ 0.80) and FCP (AUC 0.83 versus 
FIT and FCP for Identifying Mucosal Ulceration
In subgroup analysis of the 15 patients with UC (37.5%) and 7 patients with CD (17.5%) that had endoscopic evidence of 
Noninvasive Prediction Models of MH
Variables considered for regression modeling included FIT, FCP, sex, symptomatic disease activity, serologic markers of inflammation (albumin, CRP), and smoking status. Best subset selection to maximize specificity and PPV for MH found that FIT, FCP, and clinical symptomatology should be included as the most useful elements of a clinically relevant multivariate model. Odds ratios for MH are demonstrated in Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B540.
The diagnostic accuracies of 2 multivariate prediction models for MH are demonstrated in Table 3 . When both FIT (,100 ng/mL) and FCP (,250 mg/g) were low, specificity for MH was 0. 
DISCUSSION
Finding an accurate, convenient, rapid, inexpensive, reproducible, standardized noninvasive biomarker for MH in IBD has been an elusive goal. 21 Fecal testing has shown promise as an objective surrogate for intestinal inflammation. However, although elevated FIT and FCP values have demonstrated sensitivity for detecting mucosal inflammation, the specificity of low FIT and FCP for predicting MH has not been well validated. 22 In this prospective study, we demonstrate that the combination of FIT (as a surrogate measure of bleeding from mucosal ulceration) and FCP (as a surrogate measure of mucosal inflammation) is predictive of endoscopic MH in patients with IBD, particularly for those with UC. Indeed, for the clinical scenario in which a patient with IBD is in symptomatic remission, the combination of FIT ,100 ng/mL and FCP ,250 mg/g has a positive predictive value for MH of approximately 85%.
Several trials and metaanalyses have established the sensitivity of elevated FCP for detecting mucosal inflammation: Although this finding appears discordant from those seen in some of the literature, it is likely a reflection of our outcome measure: FCP is sensitive for inflammation, but we evaluated MH as our primary outcome. Other authors who have used rigorous definitions for MH as the outcome of interest have also reported lower FCP sensitivity. 24, 25 By contrast, FIT at a cutoff of 100 ng/mL was found to be highly sensitive for MH in our cohort. Our results are similar to those previously reported by Nakarai et al 13 in a cohort of 152 Japanese patients with UC (sensitivity 0.92 for FIT ,100 ng/mL and MH defined by Mayo 0) and Inokuchi et al 12 in a cohort of 71 patients with CD (sensitivity 0.96 for FIT ,52 ng/mL and MH defined by SES-CD 0). Interestingly, FIT appears more sensitive than FCP for MH: this difference may reflect the ability of FIT to detect miniscule amounts of occult blood loss in the presence of mild inflammatory disease or small ulcerations not generating significant FCP elevations, or that mucosal ulceration may persist for some time despite the reduction of inflammation in the mucosa during the course of treatment and healing. Indeed, Takashima et al 26 previously demonstrated that when strict definitions of MH are applied to the study of patients with UC (Mayo score 0, excluding Mayo score 1), the sensitivity of FIT improves as compared to FCP (95% versus 82%).
The definition of MH has not been well established. There is controversy as to whether subtle changes (such as vascular blunting consistent with Mayo 1 endoscopic disease in UC or the presence of a few, small, scattered aphthous ulcers in CD) should be included in definitions of MH. Conversely, it is unclear whether treatment should target complete mucosal normalization, including histologic remission. For our cohort, we used strict definitions of MH (UCEIS 3, CD-SES 0, Rutgeerts i0) because there is evidence that prognosis and risk of relapse between these groups of patients are not equivalent, but this is still an area of contentious debate. 27 Combining FIT, FCP, and clinical symptomatology assessment for our cohort allowed more conclusive prediction of mucosal status with modest improvements in specificity and PPV compared with the use of either FIT or FCP in isolation (see Supplemental Table 2 In our cohort, fecal testing performance characteristics are better for patients with UC than that for CD, particularly for FIT (AUC 0.88 versus 0.69, P ¼ 0.05). FIT and FCP also performed better for colonic CD than for ileal CD. Indeed, when evaluated against dedicated small bowel balloon-assisted enteroscopy, FIT has been shown to poorly correlate to the mucosal status of patients with CD without colonic disease (r ¼ 0.42). 12 This poor correlation likely relates to the optimization of FIT for detection of colorectal malignancies, and even in this context, FIT is less sensitive for right-sided colonic lesions. 28 There is more conflicting evidence related to the role FCP might play in defining CD-related inflammation. In a cohort of 87 patients with CD, D'Haens et al 24 reported that an FCP of .250 mg/g predicted endoscopically active disease with 94% sensitivity and 62% specificity, and the utility of FCP testing for CD has been corroborated by other authors. 29, 30 However, as with FIT, FCP performance may vary with disease location: Sipponen et al reported that FCP correlation was higher for patients with CD with colonic disease than for those with ileal disease, for both endoscopic score (r ¼ 0.42 versus 0.32) and histologic inflammation (r ¼ 0.56 versus 0.31). 31 FCP has now become readily available in many jurisdictions to aid gastroenterologists with providing optimal IBD care. 32 Our study highlights the similar performance characteristics of FIT as a noninvasive biomarker, particularly in UC, which warrants consideration in this setting. In fact, FIT has several advantages over FCP, including lower cost, higher throughput, benefit of automation over manual enzyme-linked immunosorbent assay, and a more stable cutoff value. 33 However, positive FIT results will need to be followed up with endoscopic evaluation, given the possibility of colorectal malignancy. The cost-effectiveness in this IBD setting has not been evaluated. Future studies should assess both cost and outcome comparisons between patients monitored by serial noninvasive testing with FIT and FCP versus endoscopic surveillance.
There are several limitations to our study. First, we used single stool sample results for analysis. Serial evaluation might improve the performance characteristics of these stool tests. In particular, for FCP, levels vary day-to-day, by time of day, and even within the same bowel movement. 34 Furthermore, gastroenterologists rarely use a single FCP measurement to make clinical decisions. 35 Rather, comparison to the patient's baseline FCP results established at the time of proven quiescent disease and comparison of trends in FCP results may be more informative. 32 Second, our sample size is limited in terms of more detailed subgroup analysis, especially when patients with CD and UC are separately stratified. For instance, the effects of variables such as CD phenotype and disease behavior were difficult to assess in this study. Finally, 6 gastroenterologists evaluated patients for endoscopic MH, but these gastroenterologists' individual findings were not independently confirmed by another endoscopist because of feasibility issues. However, our stringent definition of complete MH, as compared to findings of partial MH, means the study's criteria allowed for little subjective variability. Furthermore, all the gastroenterologists involved have advanced training in IBD assessment. In conclusion, we demonstrate in this prospectively defined cohort of patients with IBD that FIT has similar performance characteristics to FCP for predicting MH and should be considered for use in the IBD setting. FIT and FCP testing in combination with clinical symptom assessment improves specificity and predictive values for determination of MH. Further study is required to validate this multivariate model and determine its best use for prognosticating IBD-related outcomes.
